What Is ICSI and When Is It Needed? A Complete Patient Guide

What Is ICSI and When Is It Needed?

ICSI (Intracytoplasmic Sperm Injection) is a laboratory technique used within IVF in which a single sperm is injected directly into the cytoplasm of a mature egg using a fine glass needle. It was first successfully performed in 1992 by Palermo et al and has since become one of the most transformative techniques in reproductive medicine.

The Science: How ICSI Differs From Conventional IVF

In conventional IVF, approximately 50,000–100,000 prepared sperm are placed in a dish with each egg. The most competent sperm must independently bind to and penetrate the zona pellucida — the egg's outer coat — through a natural selection process. This requires: normal motility to reach the egg, intact acrosome function (the enzyme-releasing cap on the sperm head), and sufficient morphology to bind and penetrate.

In ICSI, a single sperm is immobilised and drawn into a glass pipette with an inner diameter of approximately 7 microns — narrower than a human hair. Under 400× magnification, the embryologist guides this needle through the zona pellucida and deposits the sperm directly into the egg's cytoplasm. The natural fertilisation barrier is bypassed entirely.

Fertilisation confirmation: 16–18 hours later, fertilised eggs are identified by the presence of two pronuclei (2PN) — one from the egg, one from the sperm. Normal fertilisation rates with ICSI in appropriately selected cases: 70–85% of mature (MII) eggs.

When ICSI Is Definitively Indicated

The ASRM Practice Committee (2023), ESHRE Good Practice Recommendations on ICSI (2023), and FOGSI Position Statement on Male Factor Infertility converge on the following evidence-based indications:

1. Severe oligospermia (Total Motile Sperm Count <5 million) With fewer than 5 million total motile sperm in the prepared sample, conventional IVF fertilisation rates drop to below 15–20%. ICSI achieves equivalent fertilisation to ICSI in normal-sperm cases.

2. Severe asthenospermia (Progressive motility <10%) Sperm must swim from the dish to the egg in conventional IVF. With severe motility impairment, this journey cannot be completed. ICSI bypasses this requirement entirely.

3. Surgical sperm retrieval (PESA / MESA / TESE / micro-TESE) Surgically retrieved epididymal or testicular sperm are always used with ICSI — they are available in limited quantities, often have suboptimal motility, and cannot be used in conventional IVF.

4. Previous complete conventional IVF fertilisation failure If eggs were retrieved but none fertilised in a prior IVF cycle using conventional insemination, ICSI is recommended in all subsequent cycles. Per ESHRE 2023, this is one of the strongest individual indications.

5. Severe teratospermia (<2% normal forms by Kruger strict criteria) Very poor morphology — particularly acrosomal defects (absent or abnormal acrosome cap) — prevents the acrosome reaction needed for zona penetration. ICSI bypasses this mechanism.

6. High sperm DNA fragmentation (DFI >25–30%) ICSI allows the embryologist to select the most morphologically normal sperm under magnification, partially mitigating DNA fragmentation. Using testicular sperm (lower DFI than ejaculated sperm) for ICSI is an evidence-based approach in men with very high ejaculated DFI.

7. Preimplantation genetic testing cycles (PGT-A / PGT-M) When embryos will be biopsied for genetic analysis, ICSI is preferred to eliminate the theoretical risk of extraneous adherent sperm contaminating the trophectoderm biopsy DNA.

8. Small numbers of retrieved eggs When fewer than 5 mature eggs are retrieved, ICSI is often preferred to maximise the certainty of fertilisation from each available egg — avoiding the risk of complete fertilisation failure.

When ICSI Is Routinely Used But Not Definitively Required

Many IVF centres — including most in India — use ICSI for all cycles as standard practice, regardless of semen parameters. This "universal ICSI" approach is common but contested.

The evidence against routine ICSI for normal semen: The ESHRE multicentre RCT (Bhattacharya et al, 2001) found no significant difference in live birth rates between conventional IVF and ICSI when semen parameters were normal. A 2018 Cochrane Review confirmed this: ICSI does not improve live birth rates over conventional IVF in non-male-factor cases.

The ASRM 2023 position: "ICSI should not be recommended routinely for non-male factor IVF. For couples with normal semen parameters and no prior IVF failure, conventional insemination is appropriate."

The ESHRE 2023 position: "ICSI is the treatment of choice for male factor infertility. Universal application in non-male factor cycles is not evidence-based and adds cost and potential risk without proven benefit."

Why many clinics still use universal ICSI:

• Eliminates risk of unexpected conventional fertilisation failure (approximately 5% of cycles)
• Simplifies laboratory protocol — one technique rather than two
• Allows certainty in high-cost cycles or with limited eggs
• Patient and commercial pressures

ICSI Safety: What the Evidence Shows

Fertilisation damage risk: The microinjection itself has a small risk of egg damage (1–3% of injections cause degeneration). In expert hands this is minimised. Inexperienced embryologists have higher egg loss rates — laboratory quality matters.

Birth defect risk: Large registry studies show ICSI is associated with a very modest increase in certain imprinting disorders:

• Beckwith-Wiedemann syndrome: ~0.5% (ICSI) vs ~0.3% (natural conception)
• Angelman syndrome: Slightly elevated
• Overall major congenital defect rate: Not significantly different from conventional IVF or natural conception

ACOG Committee Opinion on ART Safety: Notes the slightly elevated imprinting disorder risk and recommends counselling before ICSI. This does not contraindicate ICSI for indicated cases — the benefit substantially outweighs the very small absolute risk increase.

Y-chromosome microdeletion transmission: Men with AZFc Y-chromosome microdeletions who father sons via ICSI will transmit the deletion — their sons will also be oligospermic or azoospermic. Genetic counselling is mandatory before ICSI with azoospermia or severe oligospermia. Karyotype and Y-deletion testing is recommended before any ICSI cycle with <5 million sperm (ASRM 2022; ESHRE 2023).

Advanced ICSI Techniques

PICSI (Physiological ICSI): Sperm are selected by their ability to bind to hyaluronan (HA) — a component of the cumulus cells surrounding eggs. HA-binding capacity correlates with sperm DNA integrity and morphological maturity. The HAZMAT RCT (2019, Lancet) showed PICSI reduced miscarriage rates in couples with high DNA fragmentation. ESHRE 2023: consider PICSI when sperm DNA fragmentation is elevated.

IMSI (Intracytoplasmic Morphologically Selected Sperm Injection): Uses very high magnification (6,000–10,000×) to examine sperm morphology in extraordinary detail before injection. Limited by lack of large RCT evidence for routine use. ASRM 2023: insufficient evidence to recommend IMSI routinely; may have benefit in severe teratospermia or repeated ICSI failure.

Magnetic Activated Cell Sorting (MACS): Removes apoptotic (programmed cell death) sperm before ICSI using annexin V magnetic beads. Some evidence for improved embryo quality. Not yet standard of care.

ICSI in Practice: The Procedure Step by Step

1. The egg retrieval is performed under sedation — eggs are collected, assessed for maturity by the embryologist.
2. The surrounding cumulus cells are enzymatically removed (hyaluronidase) to expose the egg.
3. Maturity classification: Only MII (metaphase II) eggs — the majority — can be fertilised. MI and GV-stage eggs are immature and set aside.
4. The male partner's semen sample is prepared by density gradient centrifugation and swim-up to select the highest quality sperm.
5. Under a heated stage at 37°C, each MII egg is stabilised with a holding pipette.
6. A single sperm is aspirated into the injection pipette.
7. The zona pellucida is pierced, the oolemma (inner egg membrane) is gently broken, and the sperm is deposited.
8. Eggs are returned to the incubator. Fertilisation is confirmed 16–18 hours later.

Reference: ASRM Practice Committee — Intracytoplasmic Sperm Injection (ICSI), 2023. ESHRE Good Practice Recommendations — ICSI, 2023. ACOG Committee Opinion No. 671 — Perinatal Risks Associated with ART, 2016 (reaffirmed 2022). FOGSI — Position Statement on Male Infertility, 2021. WHO Laboratory Manual for Semen Analysis, 6th edition, 2021.